The comparison of animal models for premature ovarian failure established by several different source of inducers.
The objective of this study was to compare premature ovarian failure animal models established by several different source of inducers. Female ICR mice, KM mice, and SD rats were treated by cyclophosphamide at 120 mg/kg, busulfan at 12 mg/kg, cisplatin at 3 or 4 mg/kg, 4-vinylcyclohexene diepoxide at 160 mg/kg, 35% galactose food pellet, and tripterygium glycosides at 50 mg/kg, respectively. Parameters were analyzed by body weight, serum concentration level of related hormones, ovarian and uterine pathological examination. The results indicated the body weight of mice increased very slowly following single dose of cyclophosphamide (p < 0.05) with damaged ovary; repeated doses of cisplatin could induce body weight significantly decreased (p < 0.01) with a rising trend of serum LH concentration, declining tendency of serum E2 concentration and injured ovary and uterus; 4-vinylcyclohexene diepoxide also hindered the mice growing (p < 0.05) with damaged ovary and uterus; the body weight of mice feed by 35% galactose food pellet increased slowly (p < 0.05) with dramatically higher serum concentration level of galactose, albumin, and total protein (p < 0.001) and injured ovary. Busulfan and tripterygium glycosides did not present obvious evidences. In conclusion, the inducers presented their respective features in such animal models and should be appropriately applied in preventive methods.
Department of Pharmacology and Toxicology, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, China; Reproductive and Developmental Research Institute of Fudan University, China; National Population and Family Planning Key Laboratory of Contraceptives Drugs and Devices, China.
Ting
T
Zhang
Department of Pharmacology and Toxicology, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, China; Reproductive and Developmental Research Institute of Fudan University, China; National Population and Family Planning Key Laboratory of Contraceptives Drugs and Devices, China.
Dawei
D
Yan
Department of Pharmacology and Toxicology, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, China; Reproductive and Developmental Research Institute of Fudan University, China; National Population and Family Planning Key Laboratory of Contraceptives Drugs and Devices, China.
Yang
Y
Yang
Department of Pharmacology and Toxicology, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, China; Reproductive and Developmental Research Institute of Fudan University, China; National Population and Family Planning Key Laboratory of Contraceptives Drugs and Devices, China.
Aicui
A
Ma
Department of Pharmacology and Toxicology, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, China; Reproductive and Developmental Research Institute of Fudan University, China; National Population and Family Planning Key Laboratory of Contraceptives Drugs and Devices, China.
Lei
L
Li
Department of Pharmacology and Toxicology, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, China; Reproductive and Developmental Research Institute of Fudan University, China; National Population and Family Planning Key Laboratory of Contraceptives Drugs and Devices, China.
Zhonghui
Z
Wang
Department of Pharmacology and Toxicology, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, China; Reproductive and Developmental Research Institute of Fudan University, China; National Population and Family Planning Key Laboratory of Contraceptives Drugs and Devices, China.
Qi
Q
Pan
Department of Pharmacology and Toxicology, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, China; Reproductive and Developmental Research Institute of Fudan University, China; National Population and Family Planning Key Laboratory of Contraceptives Drugs and Devices, China. Electronic address: sunzy64@163.com.
Zuyue
Z
Sun
D000818:Animals; D002066:Busulfan / Q000008:administration & dosage / Q000494:pharmacology; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology; D053138:Cyclohexenes / Q000008:administration & dosage / Q000494:pharmacology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D005690:Galactose / Q000008:administration & dosage / Q000494:pharmacology; D006027:Glycosides / Q000008:administration & dosage / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D010053:Ovary / Q000187:drug effects* / Q000473:pathology*; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D029757:Tripterygium / Q000737:chemistry; D014753:Vinyl Compounds / Q000008:administration & dosage / Q000494:pharmacology
D053138:Cyclohexenes; D006027:Glycosides; D014753:Vinyl Compounds; C012606:4-vinyl-1-cyclohexene dioxide; D003520:Cyclophosphamide; D002066:Busulfan; D002945:Cisplatin; D005690:Galactose
4-Vinylcyclohexene diepoxide; Busulfan; Chemotherapy; Cisplatin; Cyclophosphamide; Galactose; Premature ovarian failure; Tripterygium glycosides